Yahoo Finance Results
- Zacks via Yahoo FinanceNov 28 13:39 PM
Teva Pharmaceutical Industries TEVA announced the limited launch of the generic version of Mylan’s MYL EpiPen (epinephrine) auto-injector of 0.3 mg for severe allergy treatment in the ...
- Market Watch4 days ago
- Motley Fool via Yahoo Finance7 days ago
- MSN News6 days ago
- Insider Monkey via Yahoo FinanceDec 11 5:53 AM
We aren't sure whether long-term interest rates will top 5% and value stocks outperform growth, but we follow hedge fund investor letters to understand where the markets and stocks might be ...
- Motley Fool via Yahoo FinanceDec 11 20:29 PM
Adamas Pharmaceuticals (NASDAQ: ADMS), a chronic disease specialist, can't seem to catch a break. Adamas' shares are now down by a staggering 71% since the full commercial launch of its ...
Par Pharmaceutical, Inc. manufactures, markets and/or distributes more than 106 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Par Pharmaceutical, Inc. develops, manufactures, and distributes generic drugs in the United States. The company was incorporated in 2003 and is based in Spring Valley, New York. Par ...
Par is an operating company of Endo International plc, a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.
Par Pharmaceutical, Inc. is a wholly-owned subsidiary of Par Pharmaceutical Companies, Inc. and a wholly-owned indirect subsidiary of Par Pharmaceutical Holdings, Inc. 2.
CPT ® - Level I codes & modifiers HCPCS - Level II codes & modifiers CDT ® Codes - Dental "D" codes ICD-10-PCS Codes, guidelines, etc. APC - Ambulatory Pmt Class. ASC - Ambulatory Surg. Center NEW!
New Jersey-based Par Pharmaceutical Companies Inc. pleaded guilty in federal court today and agreed to pay $45 million to resolve its criminal and civil liability in the company’s promotion of its prescription drug Megace ES for uses not approved as safe and effective by the Food and Drug Administration and not covered by federal health care programs.